301 related articles for article (PubMed ID: 8388987)
1. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
[TBL] [Abstract][Full Text] [Related]
3. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
[TBL] [Abstract][Full Text] [Related]
4. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
5. Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.
Capranico G; Supino R; Binaschi M; Capolongo L; Grandi M; Suarato A; Zunino F
Mol Pharmacol; 1994 May; 45(5):908-15. PubMed ID: 8190107
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Hsiang YH; Jiang JB; Liu LF
Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
[TBL] [Abstract][Full Text] [Related]
7. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
[TBL] [Abstract][Full Text] [Related]
9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
11. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
Fox ME; Smith PJ
Cancer Res; 1990 Sep; 50(18):5813-8. PubMed ID: 2168281
[TBL] [Abstract][Full Text] [Related]
12. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
13. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
14. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
15. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex.
Jayaraju D; Gopal YN; Kondapi AK
Arch Biochem Biophys; 1999 Sep; 369(1):68-77. PubMed ID: 10462441
[TBL] [Abstract][Full Text] [Related]
19. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
Capranico G; De Isabella P; Tinelli S; Bigioni M; Zunino F
Biochemistry; 1993 Mar; 32(12):3038-46. PubMed ID: 8384486
[TBL] [Abstract][Full Text] [Related]
20. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]